Cancer Screening and PET-CT in China: Different Clinical Uses

Cancer Screening and PET-CT in China: Different Clinical Uses

Start by distinguishing screening from investigation

Screening looks for cancer before symptoms develop. Investigating a symptom, clarifying an abnormal result, staging an established cancer and monitoring treatment are different clinical tasks. If you have a symptom or an unresolved finding, ask for an appropriate clinical assessment rather than choosing a screening bundle from a travel website.

A longer test list is not evidence of a better screening programme. The National Cancer Institute describes effective screening in terms of benefits as well as harms, including false alarms, missed disease and detection of abnormalities that may never cause harm. The appropriate tests depend on the cancer, personal risk and relevant clinical guidance.

PET-CT is not a universal screening test

PET uses a radiotracer to show biological activity; CT supplies anatomical images. Clinicians may use PET-CT for specific questions such as diagnosis, the extent of a cancer, response to treatment or suspected recurrence. These uses do not establish that a whole-body PET-CT is appropriate for an otherwise well person seeking a general baseline.

PET-CT involves ionising radiation and has limitations. Increased tracer uptake is not specific to cancer: inflammation can also show activity. A scan alone does not provide a definitive answer for every possible cancer, and further investigation may be necessary. Ask the clinician what question the scan would answer, whether it would change management and what alternatives exist.

Tell the clinical team about pregnancy or breastfeeding, current medicines, diabetes and allergies where relevant. Obtain instructions from the imaging service for the exact examination; do not change medication or follow generic fasting instructions from a travel guide.

What about tumour markers and genetic tests?

Blood tumour markers have clinical uses in selected contexts, but broad panels are not reliable general cancer screening. Benign conditions can raise a marker, and some cancers do not raise the measured marker. A raised value is not a cancer diagnosis, and a normal panel does not exclude cancer. Interpretation belongs with the clinical history and any indicated investigation.

Inherited cancer-risk testing asks a different question from testing a tumour to guide treatment. A clinician or genetic counsellor can assess whether personal or family history suggests a reason for testing and discuss what a result could mean for you and relatives. Genetic testing is not an automatic extra for every checkup.

Discuss a plan matched to risk

Question for the clinician	Why it matters
Am I seeking screening, diagnosis or follow-up of known cancer?	These require different pathways
Which tests are recommended for my risk and history?	Screening is cancer-specific; one scan or panel cannot substitute for all recommended tests
What could a positive or negative result mean?	Further assessment may be needed, and normal results have limits
What are the potential harms and alternatives?	Consider radiation, procedure risks and unnecessary follow-up as applicable
Who will explain results and manage the next step?	Testing without a follow-up route leaves an incomplete care plan

Evidence-supported screening options include cervical testing, mammography and colorectal screening for appropriate groups, and low-dose lung CT for selected people at increased risk. Eligibility and intervals require the applicable guidance and clinical discussion. Colonoscopy, gastroscopy, thyroid ultrasound and genetic testing should not be treated as a single universal requirement just because they appear in a commercial package.

Confirm scope and costs separately

Ask the institution for an itemised quotation only after the clinical scope is clear. Clarify consultation, imaging, laboratory work, procedures, pathology, interpretation and any follow-up charges. Do not infer a hospital's price from a cross-country headline or assume an insurer covers preventive screening, PET-CT or genetic testing.

PriumCare provides non-clinical coordination. It does not select cancer tests, interpret findings or offer a universal PET-CT screening package through this article. Confirm any coordination deliverables and fees separately from the institution's medical services.

Questions patients ask

Should everyone have a whole-body PET-CT to look for cancer?

No. A general baseline is not by itself an indication. Discuss evidence-based screening and any specific clinical question with a clinician.

Do normal tumour markers mean I do not have cancer?

No. Some cancers do not produce elevated markers, and a marker panel cannot exclude all cancers. A clinician must assess symptoms and other relevant findings.

Does a family history mean I need genetic testing?

It may warrant a risk assessment, but the history and possible implications need review first. Ask a clinician or genetic counsellor whether testing is appropriate.

Can I book a package instead of investigating a symptom?

A symptom needs an appropriate clinical assessment. Ask which department and records are needed rather than assuming a preventive package answers the problem.

Sources and editorial update

• National Cancer Institute: screening tests.
• RadiologyInfo, from ACR and RSNA: PET-CT uses, preparation and limitations.
• National Cancer Institute: tumour markers.
• National Cancer Institute: inherited cancer-risk testing.

Editorial source check: 25 October 2026; not a clinician review. This update removes the universal test bundle, unsupported international price comparisons and promise of rapid definitive answers. International educational sources explain clinical distinctions; they do not establish a Chinese institution's availability, prices or acceptance criteria.

Next step

Ask about preparing records for a clinician-led assessment, or read how to choose the appropriate doctor and hospital.